# **Special Issue**

# Advances in Pharmacogenomic Studies

## Message from the Guest Editor

Pharmacogenomics (PGx) is a field of pharmacology that addresses how genetic factors contribute to the body's response to given medications. This informs prescribing decisions and facilitates the tailoring of patient-specific drug regimens, thus improving clinical responses. Today. PGx is a well-stablished discipline in several developed countries with some clinical applications, but it is considered emergent in developing countries, and has almost no applications in undeveloped countries. This illustrates unequal development in this important field, which is an issue in many countries where this discipline could prove costeffective or even cost-saving. This Special Issue addresses the current state of pharmacogenomics, precision medicine approaches to improving drug therapies, and challenges that must be overcome to enable their clinical application. Updated research on PGx and its clinical applications is required. To this end, this Special Issue encourages researchers to submit up-to-date original research, meta-analyses, systematic reviews, case reports, clinical trials, and specific reviews on this topic.

#### **Guest Editor**

Dr. Luis Abel Quiñones

Laboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile

#### Deadline for manuscript submissions

closed (31 May 2024)



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/166296

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## **Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

